{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=31",
    "query": {
      "intervention": "Placebo equivalent",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 843,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+equivalent&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T13:31:44.972Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00590122",
      "title": "Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Parcopa",
          "type": "DRUG"
        },
        {
          "name": "carbidopa-levodopa (Sinemet)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "31 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "31 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2006-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00590122"
    },
    {
      "nct_id": "NCT04501666",
      "title": "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prurigo Nodularis"
      ],
      "interventions": [
        {
          "name": "Nemolizumab 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2020-09-11",
      "completion_date": "2023-02-21",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04501666"
    },
    {
      "nct_id": "NCT02570854",
      "title": "A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anemia, Iron-Deficiency"
      ],
      "interventions": [
        {
          "name": "CSJ137",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-09-22",
      "completion_date": "2020-05-13",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Lakewood, Colorado • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02570854"
    },
    {
      "nct_id": "NCT03018366",
      "title": "Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Deficiency",
        "Cardiovascular Disease (CVD)",
        "Functional Hypothalamic Amenorrhea",
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "17beta Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Transdermal placebo patch",
          "type": "DRUG"
        },
        {
          "name": "Progesterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2017-01-01",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03018366"
    },
    {
      "nct_id": "NCT01929161",
      "title": "Study of Wellness Behaviors as a Function of Oxytocin vs Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sustained Positive Emotions",
        "Sustained Positive Behavior Change"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for oxytocin)",
          "type": "DRUG"
        },
        {
          "name": "Lovingkindness Meditation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Mindfulness Meditation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "35 Years to 64 Years"
      },
      "enrollment_count": 239,
      "start_date": "2013-09",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-07-18",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929161"
    },
    {
      "nct_id": "NCT00256854",
      "title": "Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Restless Legs Syndrome",
        "Restless Legs Syndrome (RLS)"
      ],
      "interventions": [
        {
          "name": "Ropinirole IR 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole IR 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole IR 1 mg Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole IR 2 mg Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole CR 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole CR 3 mg",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole CR 2 mg Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ropinirole CR 3 mg Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 135,
      "start_date": "2005-11-14",
      "completion_date": "2006-09-21",
      "has_results": true,
      "last_update_posted_date": "2019-03-15",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 30,
      "location_summary": "Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00256854"
    },
    {
      "nct_id": "NCT01617655",
      "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for alirocumab)",
          "type": "DRUG"
        },
        {
          "name": "Lipid Modifying Therapy (LMT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2012-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-10-04",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 14,
      "location_summary": "Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more",
      "locations": [
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01617655"
    },
    {
      "nct_id": "NCT00965458",
      "title": "Inducing Remission in Type 1 Diabetes With Alefacept",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "New-onset Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Alefacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 49,
      "start_date": "2011-03",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-06",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00965458"
    },
    {
      "nct_id": "NCT01493596",
      "title": "A Safety, Tolerability and Pharmacokinetic Study of CPP-115",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependency"
      ],
      "interventions": [
        {
          "name": "CPP-115",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 55,
      "start_date": "2011-12",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2021-04-20",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01493596"
    },
    {
      "nct_id": "NCT05637879",
      "title": "Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "Glecaprevir/pibrentasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "White River Junction Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 92,
      "start_date": "2023-12-18",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-11-16T13:31:44.972Z",
      "location_count": 1,
      "location_summary": "White River Junction, Vermont",
      "locations": [
        {
          "city": "White River Junction",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05637879"
    }
  ]
}